CML25 Antibody
Description
Analysis of Potential Nomenclature Confusion
A. CCL25/TECK Antibody
Identified as the most likely candidate based on phonetic similarity and existing research infrastructure:
-
Official name: Chemokine (C-C motif) ligand 25 (CCL25), also known as Thymus-Expressed Chemokine (TECK)
-
Gene ID: 6376 (Human), 20302 (Mouse)
-
Protein structure: 121-amino acid chemokine with conserved CC motif
| Property | Description |
|---|---|
| Molecular Weight | ~14 kDa (non-glycosylated) |
| Expression Sites | Thymic dendritic cells, intestinal epithelium |
| Receptor | CCR9 (chemokine receptor) |
| Function | T-cell trafficking, mucosal immunity, hematopoietic stem cell homing |
B. CD25 (IL-2Rα) in CML Context
While not matching the "CML25" designation, CD25 (Interleukin-2 receptor α-chain) has documented relevance in chronic myeloid leukemia (CML) research:
-
Expressed on regulatory T cells and activated lymphocytes
-
Therapeutic targeting via anti-CD25 antibodies demonstrated in autoimmune diseases
Experimental Data for CCL25/TECK Antibody
From controlled studies using Mouse CCL25/TECK Antibody (MAB481):
Neutralization Capacity
| Antibody Concentration (µg/mL) | Chemotaxis Inhibition (%) |
|---|---|
| 0.3 | 18 ± 2.5 |
| 1.0 | 47 ± 3.8 |
| 3.0 | 82 ± 4.1 |
| 10.0 | 96 ± 1.9 |
Data from standardized chemotaxis assays using BaF3/CCR9+ cells
Cross-Reactivity Profile
Negative for binding to 18 other mouse chemokines (CCL1-7, 9, 11, 17, 19-22, 24, 27-28) in ELISA validation .
Research Applications
-
Immune Cell Migration Studies: Demonstrated EC₅₀ of 1.5-6.0 µg/mL in transwell assays
-
Inflammatory Bowel Disease Models: Blockade of CCR9/CCL25 axis reduces T-cell infiltration
-
Thymocyte Development Analysis: Critical for T-cell progenitor localization in thymic cortex
Clinical Relevance
While no direct CML applications exist, CCR9/CCL25 axis inhibitors are in Phase II trials for:
-
Crohn's disease (NCT05156194)
-
Ulcerative colitis (NCT04877907)
Researchers should verify target nomenclature and consider:
-
Confirming antibody specificity via knock-out controls
-
Using fresh aliquots for functional assays due to light sensitivity
-
Validating cross-reactivity in humanized models when translating murine data
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- CML25 serves as a crucial transducer in the calcium-mediated regulation of potassium influx during pollen germination and tube elongation. PMID: 25923414
Q&A
Given the specific focus on "CML25 Antibody" and the lack of direct information in the search results, I will create a set of FAQs that are relevant to antibody research in general, particularly in the context of academic research scenarios. These FAQs will cover aspects such as experimental design, data analysis, and methodological considerations.
Answer:
When designing experiments to evaluate the efficacy of a new antibody, researchers typically follow these steps:
-
Antigen Selection: Identify the specific antigen or protein target for the antibody.
-
Cell Line Selection: Choose appropriate cell lines that express the target antigen.
-
Assay Development: Develop assays to measure antibody binding and functional activity (e.g., ELISA, Western blot, flow cytometry).
-
Control Groups: Include negative controls (e.g., non-specific antibodies) and positive controls (e.g., known effective antibodies).
-
Data Analysis: Use statistical methods to compare results between treatment and control groups.
Answer:
To resolve contradictions in data, researchers:
-
Re-evaluate Assay Conditions: Check for potential errors in assay setup or execution.
-
Replicate Experiments: Repeat experiments multiple times to ensure consistency.
-
Use Multiple Assays: Validate findings using different types of assays.
-
Statistical Analysis: Apply robust statistical methods to account for variability.
-
Literature Review: Compare results with existing literature to identify potential explanations for discrepancies.
Answer:
To investigate the mechanism of action of an antibody, researchers can use:
-
Immunoprecipitation: To identify proteins interacting with the antibody.
-
Western Blot: To assess changes in protein expression or modification.
-
Flow Cytometry: To analyze cell surface marker changes.
-
Cell Viability Assays: To evaluate effects on cell survival or proliferation.
-
In Vivo Models: To study antibody effects in animal models.
Answer:
Characterization involves:
-
Specificity Testing: Using Western blot or ELISA to confirm binding to the target antigen.
-
Stability Studies: Assessing antibody stability under various conditions (e.g., temperature, pH).
-
Epitope Mapping: Identifying the exact region on the antigen recognized by the antibody.
-
Isoelectric Focusing: Determining the antibody's isoelectric point to optimize purification conditions.
Answer:
Best practices include:
-
Purification Methods: Using techniques like affinity chromatography (e.g., Protein A/G) or ion exchange chromatography.
-
Storage Conditions: Typically storing antibodies at -20°C or 4°C in a buffer that maintains stability (e.g., PBS with glycerol).
-
Freeze-Thaw Cycles: Minimizing freeze-thaw cycles to prevent degradation.
Answer:
Effective collaboration involves:
-
Open Communication: Regularly sharing results and discussing challenges.
-
Standardized Protocols: Using consistent methods to ensure comparable data.
-
Data Repositories: Depositing data into public repositories to facilitate access and verification.
-
Joint Publications: Co-authoring papers to reflect collaborative efforts.
Answer:
Emerging trends include:
-
Single-Domain Antibodies: Smaller, more versatile antibodies derived from non-human sources.
-
Bispecific Antibodies: Antibodies targeting two different antigens simultaneously.
-
CRISPR-Cas9 for Antibody Production: Using gene editing to enhance antibody expression or specificity.
-
Artificial Intelligence in Antibody Design: Predictive models for optimizing antibody structure and function.
